Skip to main content

A Phase 1b Study of CG0070 combined with nivolumab in cisplatin ineligible patients with muscle invasive bladder cancer

Publication ,  Conference
Li, R; Sexton, W; Spiess, P; Gilbert, S; Pow-Sang, J; Zhang, J; Borjas, G; Grandi, P; Burke, J; Jain, R; Conejo-Garcia, J
Published in: CANCER RESEARCH
2022

Duke Scholars

Published In

CANCER RESEARCH

EISSN

1538-7445

ISSN

0008-5472

Publication Date

2022

Volume

82

Issue

12

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3101 Biochemistry and cell biology
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Li, R., Sexton, W., Spiess, P., Gilbert, S., Pow-Sang, J., Zhang, J., … Conejo-Garcia, J. (2022). A Phase 1b Study of CG0070 combined with nivolumab in cisplatin ineligible patients with muscle invasive bladder cancer. In CANCER RESEARCH (Vol. 82).
Li, Roger, Wade Sexton, Phillipe Spiess, Scott Gilbert, Julio Pow-Sang, Jingsong Zhang, Gustavo Borjas, et al. “A Phase 1b Study of CG0070 combined with nivolumab in cisplatin ineligible patients with muscle invasive bladder cancer.” In CANCER RESEARCH, Vol. 82, 2022.
Li R, Sexton W, Spiess P, Gilbert S, Pow-Sang J, Zhang J, et al. A Phase 1b Study of CG0070 combined with nivolumab in cisplatin ineligible patients with muscle invasive bladder cancer. In: CANCER RESEARCH. 2022.
Li R, Sexton W, Spiess P, Gilbert S, Pow-Sang J, Zhang J, Borjas G, Grandi P, Burke J, Jain R, Conejo-Garcia J. A Phase 1b Study of CG0070 combined with nivolumab in cisplatin ineligible patients with muscle invasive bladder cancer. CANCER RESEARCH. 2022.

Published In

CANCER RESEARCH

EISSN

1538-7445

ISSN

0008-5472

Publication Date

2022

Volume

82

Issue

12

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3101 Biochemistry and cell biology
  • 1112 Oncology and Carcinogenesis